EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

New Era of Immune-Based Therapy in Intrahepatic Cholangiocarcinoma

Etsushi Kawamura iD, Tsutomu Matsubara iD, Norifumi Kawada

Cancers · 06.08.2023 · 15 (15) · 3993

DOI: 10.3390/cancers15153993 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 06.08.2023. Verfasst von Etsushi Kawamura und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatology, Graduate School of Medicine, Osaka Metropolitan University, Osaka 545-8585, Japan. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kaken Pharmaceutical (Japan), Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Intrahepatic cholangiocarcinoma (CC) accounts for approximately 20% of all biliary tract cancer (BTC) cases and 10–15% of all primary liver cancer cases. Many patients are diagnosed with unresectable BTC, and, even among patients with resectable BTC, the 5-year survival rate is approximately 20%. The BTC incidence rate is high in Southeast and East Asia and has increased worldwide in recent years. Since 2010, cytotoxic chemotherapy, particularly combination gemcitabine + cisplatin (ABC-02 trial), has been the first-line therapy for patients with BTC. In 2022, a multicenter, double-blind, randomized phase 3 trial (TOPAZ-1 trial) examined the addition of programmed death-ligand 1 immunotherapy (durvalumab) to combination gemcitabine + cisplatin for BTC treatment, resulting in significantly improved survival without notable additional toxicity. As a result of this trial, this three-drug combination has become the new standard first-line therapy, leading to notable advances in BTC management for the first time since 2010. The molecular profiling of BTC has continued to drive the development of new targeted therapies for use when first-line therapies fail. Typically, second-line therapy decisions are based on identified genomic alterations in tumor tissue. Mutations in fibroblast growth factor receptor 1/2/3, isocitrate dehydrogenase 1/2, and neurotrophic tyrosine receptor kinase A/B/C are relatively frequent in intrahepatic CC, and precision medicines are available that can target associated pathways. In this review, we suggest strategies for systemic pharmacotherapy with a focus on intrahepatic CC, in addition to presenting the results and safety outcomes of clinical trials evaluating immune checkpoint inhibitor therapies in BTC.

Schlagwörter

Stichwörter der Autor:innen

biliary tract cancerimmune checkpoint inhibitorsimmunotherapyintrahepatic cholangiocarcinomaprecision medicine

Autor:innen und Institutionen

  • Department of Hepatology, Graduate School of Medicine, Osaka Metropolitan University, Osaka 545-8585, Japan.
  • Department of Anatomy and Regenerative Biology, Graduate School of Medicine, Osaka Metropolitan University, Osaka 545-8585, Japan.

ORCID-Profile: Etsushi Kawamura, Tsutomu Matsubara

Förderung

  • Kaken Pharmaceutical (Japan)
  • Japan Society for the Promotion of Science

Zitieren

APA

Kawamura, E., Matsubara, T., & Kawada, N. (2023). New Era of Immune-Based Therapy in Intrahepatic Cholangiocarcinoma. Cancers, 15(15), 3993. https://doi.org/10.3390/cancers15153993

Vancouver

Kawamura E, Matsubara T, Kawada N. New Era of Immune-Based Therapy in Intrahepatic Cholangiocarcinoma. Cancers. 2023;15(15):3993. doi:10.3390/cancers15153993

BibTeX
@article{Kawamura2023,
  author = {Kawamura, Etsushi and Matsubara, Tsutomu and Kawada, Norifumi},
  title = {New Era of Immune-Based Therapy in Intrahepatic Cholangiocarcinoma},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {15},
  pages = {3993},
  doi = {10.3390/cancers15153993}
}
Kostenlos starten →